|
Variable
|
Categories
|
Total
|
NHW
|
AA
|
HW
|
P
1
|
|---|
|
N
|
%
|
N
|
%
|
N
|
%
|
N
|
%
|
|---|
|
Total
| |
366
|
100
|
58
|
16
|
73
|
20
|
235
|
64
| |
|
Age (years)
|
< 50
|
95
|
26
|
18
|
31
|
19
|
26
|
58
|
25
|
0.613
|
|
≥ 50
|
271
|
74
|
40
|
69
|
54
|
74
|
177
|
75
| |
|
Mean (SD)
|
56.0 (9.1)
|
55.6 (9.1)
|
54.9 (9.2)
|
56.5 (9.1)
| |
|
BMI (kg/m2)
|
< 25
|
96
|
26
|
29
|
50
|
12
|
16
|
55
|
23
|
< 0.0001
|
|
25–29.9
|
124
|
34
|
16
|
28
|
17
|
23
|
91
|
39
| |
|
≥ 30
|
146
|
40
|
13
|
22
|
44
|
60
|
89
|
38
| |
|
Mean (SD)
|
29.3 (6.4)
|
26.6 (6.3)
|
32.6 (8.4)
|
28.9 (5.2)
| |
|
Smoking status
|
Never
|
240
|
66
|
37
|
64
|
51
|
70
|
152
|
64
|
0.490
|
|
Former
|
107
|
29
|
20
|
34
|
17
|
23
|
70
|
30
| |
|
Current
|
19
|
5
|
1
|
2
|
5
|
7
|
13
|
6
| |
|
Sum of 12 comorbid conditions2
|
0
|
147
|
40
|
28
|
48
|
19
|
26
|
100
|
43
|
0.119
|
|
1
|
137
|
37
|
20
|
34
|
32
|
44
|
85
|
36
| |
|
2
|
60
|
16
|
7
|
12
|
18
|
25
|
35
|
15
| |
|
≥ 3
|
22
|
6
|
3
|
5
|
4
|
5
|
15
|
6
| |
|
Tumor stage
|
0
|
74
|
20
|
7
|
12
|
14
|
19
|
53
|
23
|
0.003
|
|
IA-B
|
180
|
49
|
37
|
64
|
28
|
38
|
115
|
49
| |
|
IIA-B
|
90
|
25
|
13
|
22
|
29
|
40
|
48
|
20
| |
|
IIIA-C
|
22
|
6
|
1
|
2
|
2
|
3
|
19
|
8
| |
|
ER
|
Positive
|
279
|
76
|
43
|
74
|
49
|
67
|
187
|
80
|
0.072
|
|
Negative
|
86
|
23
|
15
|
26
|
24
|
33
|
47
|
20
| |
|
PR
|
Positive
|
243
|
66
|
36
|
62
|
44
|
60
|
163
|
69
|
0.243
|
|
Negative
|
122
|
33
|
22
|
38
|
29
|
40
|
71
|
30
| |
|
HER2
|
Positive
|
31
|
8
|
4
|
7
|
6
|
8
|
21
|
9
|
0.730
|
|
Negative
|
275
|
75
|
50
|
86
|
56
|
77
|
169
|
72
| |
|
Triple negative
|
No
|
294
|
80
|
47
|
81
|
52
|
71
|
195
|
83
|
0.005
|
|
Yes
|
54
|
15
|
8
|
14
|
20
|
27
|
26
|
11
| |
|
Axillary surgery
|
None/SLNB
|
248
|
68
|
39
|
67
|
54
|
74
|
155
|
66
|
0.439
|
|
ALND
|
118
|
32
|
19
|
33
|
19
|
26
|
80
|
34
| |
|
Chemotherapy
|
No
|
195
|
53
|
31
|
53
|
39
|
53
|
125
|
53
|
0.999
|
|
Yes
|
171
|
47
|
27
|
47
|
34
|
47
|
110
|
47
| |
|
Hormone therapy/initiation time
|
None/after RT
|
178
|
49
|
37
|
64
|
41
|
56
|
100
|
43
|
0.015
|
|
Aromatase inhibitor before RT
|
98
|
27
|
9
|
16
|
14
|
19
|
75
|
32
| |
|
Aromatase inhibitor during RT
|
14
|
4
|
3
|
5
|
2
|
3
|
9
|
4
| |
|
Tamoxifen before RT
|
64
|
17
|
6
|
10
|
12
|
16
|
46
|
20
| |
|
Tamoxifen during RT
|
12
|
3
|
3
|
5
|
4
|
5
|
5
|
2
| |
|
RT fractionation
|
Conventional
|
306
|
84
|
45
|
78
|
64
|
88
|
197
|
84
|
0.298
|
|
Hypo
|
60
|
16
|
13
|
22
|
9
|
12
|
38
|
16
| |
|
Total RT dose (Gy)
|
< 60
|
107
|
29
|
21
|
36
|
18
|
25
|
68
|
29
|
0.348
|
|
≥ 60
|
259
|
71
|
37
|
64
|
55
|
75
|
167
|
71
| |
|
Mean (SD)
|
58.2 (4.8)
|
58.4 (4.6)
|
58.7 (4.9)
|
58.0 (4.8)
| |
|
Boost
|
Yes
|
331
|
90
|
56
|
97
|
65
|
89
|
210
|
89
|
0.225
|
|
No
|
35
|
10
|
2
|
3
|
8
|
11
|
25
|
11
| |
|
Breast volume (cc)
|
< 892.1 (median)
|
183
|
50
|
38
|
66
|
20
|
27
|
125
|
53
|
< 0.001
|
|
≥ 892.1 (median)
|
179
|
49
|
20
|
34
|
52
|
71
|
107
|
46
| |
|
Mean (SD)
|
996 (532)
|
799 (464)
|
1254 (645)
|
965 (479)
| |
|
Pre-RT pain
|
Mean (SD)
|
1.7 (2.1)
|
1.0 (1.3)
|
2.0 (2.5)
|
1.8 (2.1)
|
0.023
|
|
Post-RT pain
|
Mean (SD)
|
2.8 (2.5)
|
1.9 (1.7)
|
3.2 (2.6)
|
2.8 (2.6)
|
0.013
|
- 1P values from the chi-square test or Fisher's exact test, or ANOVA, excluding missing. Significant findings are in italics
- 2Sum of 12 patient-reported comorbid conditions: diabetes, hypertension, heart disease, lung disease, thyroid disease, cirrhosis liver, stroke, chronic bronchitis, hepatitis, tuberculosis, and 2 others
- Abbreviations: NHW non-Hispanic whites, AA black or African American, HW Hispanic whites, SD standard deviation, BMI body mass index, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, RT radiotherapy
